| 杨夏楠,赵丹丹,司晗,等.内凝集蛋白 1在卵巢癌中的生物信息学分析及体外抗增殖作用研究[J].安徽医药,2024,28(9):1885-1889. |
| 内凝集蛋白 1在卵巢癌中的生物信息学分析及体外抗增殖作用研究 |
| Bioinformatics analysis of intelectin-1 in ovarian cancer and its anti-proliferation effect in vitro |
| |
| DOI：10.3969/j.issn.1009-6469.2024.09.041 |
| 中文关键词: 卵巢肿瘤 癌基因 内凝集蛋白 1 生物信息学 细胞增殖 预后 |
| 英文关键词: Ovarian neoplasms Oncogenes Intelectin-1 Bioinformatics Cell proliferation Prognosis |
| 基金项目: |
|
| 摘要点击次数: 664 |
| 全文下载次数: 322 |
| 中文摘要: |
| 目的分析内凝集蛋白 1(ITLN1)在卵巢癌中的生物信息学信息及其体外抗增殖作用。方法 2021年 3月至 2022年 3月，采用基因表达数据库( GEO)来分析筛选卵巢癌组织中的差异基因。利用基因表达谱交互分析工具( GEPIA)来分析 ITLN1在卵巢癌肿瘤组织与正常组织中的表达水平。利用癌症基因组图谱 -基因型组织表达( TCGA-GTEx)数据制作受试者操作特征曲线(ROC曲线)利用 Kaplan Meier-plotter分析 ITLN1低表达或高与卵巢癌病人总生存率的曲线关系。利用 LinkedOmics筛选 ITLN1在卵巢癌中的，相关基因，然后采用京都基因与基因组数据库( KEGG)进行通路富集分析。细胞实验分组:空载体对照组(vector)，TLN1过表达载体组( TLN1)ITLN1+740 Y-P组。通过蛋白质印迹法检测 ITLN1、磷脂酰肌醇 3激酶( PI3K)、磷酸化 PI3K(p-PI3K)、蛋白激酶 B(Akt)以及磷酸，化 Akt(p-Akt)在卵巢癌细胞中蛋白表达水平。通过 5-乙炔基 -2'-脱氧尿苷( EdU)法与细胞计数试剂盒( CCK-8)法检测细胞增殖。结果 ITLN1在卵巢癌组织( 0.45±0.17)和人卵巢癌细胞株 A2780(0.72±0.08)、 CAOV3(0.57±0.05)、 SKOV3(0.44±0.08)中的表达量均显著降低( P<0.05)。并且， ITLN1在卵巢癌中具有诊断价值(ROC曲线下面积为 0.88)ITLN1高表达组的卵巢癌病人总生存率高于 ITLN1低表达组(风险比 0.74，P<0.05)。ITLN1通过抑制 PI3K/Akt信号通路从而降低，卵巢癌细胞的增殖能力( 0.55±0.02)。结论 ITLN1表达水平可以成为卵巢癌病人的预后判断标志物，是潜在的卵巢癌治疗的靶点。这为卵巢癌的分子靶向治疗提供了新的理论基础。 |
| 英文摘要: |
| Objective To study the bioinformatics information of intelectin-1 (ITLN1) in ovarian cancer and its anti-proliferation ef- fect in vitro.Methods From March 2021 to March 2022, Gene Expression Omnibus (GEO) was used to analyze and screen differentialgenes in ovarian cancer tissues. Gene Expression Profiling Interactive Analysis (GEPIA) was used to analyze the expression levels ofITLN1 in ovarian cancer tumor tissues and normal tissues. The Cancer Genome Atlas-Genotypic tissue expression (TCGA-GTEx) data were used to make Receiver Operating Characteristic (ROC) curves, and Kaplan Meier-Plotter was used to analyze the curve relation-ship between low or high ITLN1 expression and overall survival rate of ovarian cancer patients. Genes related to ITLN1 in ovarian can-cer were screened using LinkedOmics, and pathway enrichment analysis was performed using the Kyoto Encyclopedia of Genes and Ge-nomes (KEGG). Cell experiments grouping were empty vector control group (vector), TLN1 overexpression vector group (TLN1), andITLN1+740 Y-P group. Western blotting assay was performed to detect the relative protein expression levels of ITLN1, phosphoinosit- ide 3-kinase (PI3K), phosphorylated-PI3K (p-PI3K), protein kinase B (Akt), and phosphorylated-Akt (p-Akt) in ovarian cancer cells. Cell proliferation was detected by 5-Ethynyl-2'-deoxyuridine (EdU) method and Cell Counting Kit-8 assay (CCK-8).Results The ex- pressions of ITLN1 in ovarian cancer tissues (0.45±0.17) and cells [A2780 (0.72±0.08), CAOV3 (0.57±0.05), SKOV3 (0.44±0.08)] weresignificantly decreased (P<0.05). In addition, ITLN1 had diagnostic value in ovarian cancer (area under curve 0.88). Analysis of overallsurvival curve of patients showed that the overall survival rate of patients with high ITLN1 expression was significantly higher than thatof patients with low ITLN1 expression (hazard ratio 0.74, P<0.05). ITLN1 reduced the proliferation (0.55±0.02) of ovarian cancer cells by inhibiting the PI3K/Akt signaling pathway.Conclusions These results suggested that ITLN1 level can be a prognostic marker forovarian cancer patients and a potential therapeutic target for ovarian cancer. This study provides a new theoretical basis for moleculartargeted therapy of ovarian cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
